ANEB (Anebulo Pharmaceuticals, Inc.) EV/Sales Multiple

Official company branding of Anebulo Pharmaceuticals, Inc. (ANEB)

The primary driver for Anebulo Pharmaceuticals (ANEB) is the development of cannabinoid intoxication antidotes for hospitals. The price-to-sales multiple reflects market expectations, with the value holding around 0.00. Stability is ensured by GMP-certified facilities for pilot batches, while high margins are achieved through established express logistics for controlled substances to emergency departments.

Anebulo Pharmaceuticals, Inc. (ANEB) - Enterprise Value-to-Revenue Ratio from 11/23/2025 to 03/07/2026

ANEB (Anebulo Pharmaceuticals, Inc.): analytical breakdowns and indicator data

- cash balance and cash flow data:
Fundamental company valuation:Anebulo Pharmaceuticals ANEB
Product sample of anebulo.com

This indicator is calculated as the ratio of total enterprise value to sales, allowing for an assessment of the asset's real value without distortions caused by debt load. By analyzing the Enterprise Value to revenue ratio, an investor can determine the premium paid for the potential of Anebulo Pharmaceuticals (ANEB) to create unique antidotes, the demand for which is growing alongside the global legalization of cannabis.